Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Oct. 23, 2014

View Archived Issues

Inside the Beltway:FDA custom device final guidance allows five devices per indication

Beta-O2 treats first patient in Bio-Artificial pancreas trial

Daily M&A: OxySure Systems and Estill to merge, financial details not disclosed

Financings: Nanosphere's 40M share offering could raise more than $21 million

World in Review: Foundation Medicine, WuXi, to offer profiling to biopharma in China

Grants:Antigen Discovery gains SBIR from NIH to develop HIV Microarray chip

Agreeements/contracts

Briefly Noted

Products

MDD's Orthopedics Extra

United European Gastroenterology Meeting: Robotic colonoscopy said to eliminate pain, reduces costs

VIENNA — Discomfort is the leading reason people give for not undergoing a colonoscopy, and the leading cause of non-compliance with this gold standard for colorectal cancer screening. Read More

Reimbursement Review:Rising middle class offset by price pressure in India med-tech market